PTPatricia Troncoso

Patricia Troncoso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Troncoso has a total of 140 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    De Novo and Postradiation Adenocarcinoma of the Urethra

    by Miao Zhang, Raghu Vikram, Junhyoun Sung, Peng Wei, Kanishka Sircar, Patricia Troncoso, Curtis Pettaway, Pheroze Tamboli, Bogdan Czerniak

    Herein, we report the results of clinicopathologic and radiographic analyses of 55 patients with primary adenocarcinoma of the urethra. Their ages at diagnosis ranged from 42 to 88 years (mean: 66 y). Twenty-six patients were male and 29 were female (ratio: 1.0:1.1). We noted 2 distinct groups of cases: de novo urethral adenocarcinoma (n=45) and urethral adenocarcinoma in patients after radiation therapy for prostatic adenocarcinoma (n=10), defined as postradiation adenocarcinoma. Postradiation tumors developed 8 to 25 years (mean: 15.6 y) after radiation therapy. Eight patients underwent brachytherapy. Among the 45 patients with de novo adenocarcinoma, 29 were female, for a female-to-male ratio of 1.8 to 1.0. In 17 female patients with de novo urethral adenocarcinoma, tumors developed in a urethral diverticulum. Histologically, urethral adenocarcinomas exhibited adenocarcinoma not otherwise specified or clear cell, mucinous, enteric, and adenoid cystic carcinoma morphology. In 2 cases of de novo adenocarcinoma and 3 cases of postradiation adenocarcinoma, the tumors progressed to sarcomatoid carcinoma. The mean disease-specific survival time for the entire cohort was 100.35 months. As reflected by the Kaplan-Meier curves for these patients, the patterns of disease-specific survival were similar in the de novo and postradiation groups.

  • Open Access

    Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer

    by Spyridon P. Basourakos, John W. Davis, Brian F. Chapin, John F. Ward, Curtis A. Pettaway, Louis L. Pisters, Neema Navai, Mary F. Achim, Xuemei Wang, Hsiang‐Chun Chen, et al.

    Objectives: To evaluate the role of caveolin‐1 (Cav‐1) as a predictor of disease reclassification ( DR ) in men with early prostate cancer undergoing active surveillance ( AS ). Patients and Methods: We analysed archived plasma samples prospectively collected from patients with early prostate cancer in a single‐institution AS study. Of 825 patients enrolled, 542 had ≥1 year of follow‐up. Baseline and longitudinal plasma Cav‐1 levels were measured using an enzyme‐linked immunosorbent assay. Tumour volume or Gleason grade increases were criteria for DR . Logistic regression analyses were used to assess associations between clinicopathological characteristics and reclassification risk. Results: In 542 patients, 480 (88.6%) had stage cT 1c disease, 542 (100.0%) had a median prostate‐specific antigen level of 4.1 ng/mL, and 531 (98.0%) had a median Cancer of the Prostate Risk Assessment score of 1. In all, 473 (87.3%) had a Gleason score of 3+3. After a median of 3.1 years of follow‐up, disease was reclassified in 163 patients (30.1%). The mean baseline Cav‐1 level was 2.2 ± 8.5 ng/mL and the median 0.2 ng/mL (range, 0–85.5 ng/mL). In univariate analysis, baseline Cav‐1 was a significant predictor for risk of DR (odds ratio [ OR ] 1.82, 95% confidence interval [ CI ] 1.24–2.65; P = 0.002). In multivariate analysis, with adjustments for age, tumour length, group risk stratification and number of positive cores, reclassification risk associated with Cav‐1 remained significant ( OR 1.91, 95% CI 1.28–2.84; P = 0.001). Conclusion: Baseline plasma Cav‐1 level was an independent predictor of disease classification. New methods for refining AS and intervention may result.


  • Genetic ancestry and prostate cancer susceptibility SNPs in Puerto Rican and African American men

    by Margarita Irizarry‐Ramírez, Rick A. Kittles, Xuemei Wang, Jeannette Salgado‐Montilla, Graciela M. Nogueras‐González, Ricardo Sánchez‐Ortiz, Lourdes Guerrios, Keila Rivera, Ebony Shah, Ina Prokhorova, et al.

    Background: The Puerto Rican (PR) population is a racially admixed population that has a high prostate cancer (PCa) mortality rate. We hypothesized in this pilot study that West African Ancestry (WAA) was associated with PCa in this heterogeneous (PR) population.Methods: A case/case and case/control study was performed. Controls, 207 African American (AA) and 133 PR were defined as men with no PCa, a serum PSA < 2.5 ng/mL and a negative rectal examination. Cases were patients with pathological specimens from radical prostatectomies (RP) (291 PR and 200 AA). DNA was extracted from whole blood of controls and from paraffin embedded normal seminal vesicle from the RPs. We assessed the association of PCa and aggressiveness with genetic ancestry using an ancestry informative marker panel (AIMs) and Wilcoxon rank‐sum test and the association of PCa and aggressiveness with 15 previously PCa associated SNPs using Chi square test. Gleason Score (GS) and tumor stage (TS) were used to define low risk (GS ≤ 7[3 + 4]), TS ≤ pT2) and high risk (GS≥ 7[4 + 3], TS > pT2) PCa. Statistical analyses were done using SAS.Results: No difference in overall percent WAA was found between PR cases and controls. Among PR or AA cases WAA was not associated with disease severity based upon risk group, Gleason score or stage. Among AA controls WAA was significantly higher than in cases. The SNP rs7824364 (chromosome 8q24) PCa risk allele was significantly increased among cases versus controls for both AA (P < 0.0001) and PR (P = 0.0001) men. PR men with ≥1 risk allele exhibited a higher percent of WAA (39% vs 29%, P = 0.034).Conclusion: The SNP rs7824364, a local marker of WAA in the 8q24 region was associated with PCa among both AA and PR men and with increased WAA among PR men. This novel relationship of PCA risk loci, WAA with PCa and its phenotype among PR men deserves further study.


  • Investigation of mechanisms of resistance to ipilimumab therapy with a pre-surgical trial in patients with high-risk, localized prostate cancer.

    by Jianjun Gao, John Francis Ward, Curtis Alvin Pettaway, Lewis Z Shi, Sumit Kumar Subudhi, Luis M Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou, et al.

    5081 Background: Anti-CTLA-4 therapy ipilimumab (BMS) has led to clinical benefit in patients with metastatic melanoma. However, in multiple clinical trials in patients with prostate cancer, ipilimumab has not demonstrated significant clinical benefit. To identify potential immune inhibitory pathways responsible for resistance to ipilimumab therapy, we evaluated tumor samples from a pre-surgical clinical trial and performed correlative laboratory studies. Methods: We carried out a pre-surgical clinical trial with androgen deprivation therapy (ADT), (leuprolide acetate, Tap Pharmaceuticals) plus ipilimumab in patients with localized, high-risk prostate cancer. Each patient received one injection of leuprolide (22.5 mg) on week 0 and ipilimumab (10 mg/kg) on weeks 1 and 4. Patients then underwent surgery at week 8. Tumor tissues were collected at baseline and then at surgery for flow cytometry, IHC, multiplex immunofluorescence, and gene profiling analyses. In vitro studies were carried out for functional analysis. Results: Sixteen patients completed treatment with ipilimumab plus ADT and surgery. We observed a significant increase of immune cells including T cells and macrophages into prostate tumors after ipilimumab therapy, similar to data observed in ipilimumab-treated melanoma samples. However, compared to melanoma tumors, we found higher expression of PD-L1 and VISTA inhibitory molecules on CD68+ macrophages in prostate tumors. Interestingly, PD-L1 and VISTA were expressed on distinct subset of CD68+ macrophages, with high expression of CD163, suggesting an M2 subtype. In vitro studies demonstrated that engagement of PD-L1 and/or VISTA pathways inhibited T cell responses. Co-culture with monocytes resulted in suppression of T cell function, which can be reversed with anti-VISTA blocking antibody. Conclusions: These data suggest that evolving compensatory inhibitory pathways including PD-L1 and VISTA may mediate resistance of prostate cancer to ipilimumab therapy. Concurrent blockade of other immune checkpoints such as PD1/PD-L1 and/or VISTA may be necessary to provide significant clinical benefits for patients with prostate cancer. Clinical trial information: NCT01194271.


  • Linking tumor mutational load to clinical responses to ipilimumab (IPI) in men with advanced prostate cancer (PCa).

    by Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-Jiun Wu, Jianjun Gao, Luis M Vence, Jorge M Blando, Paul Gettys Corn, et al.

    5065 Background: Tumor mutational load and neoantigens have been associated with responses to immune checkpoint therapies in patients (pts) with melanoma and lung cancer. We designed a clinical trial (NCT02113657) in advanced PCa to determine whether the induction of antitumor responses by IPI correlate with T cell responses to PCa neoantigens. Methods: All advanced PCa pts enrolled into this study had sufficient DNA/RNA from tumor tissue obtained prior to receiving IPI (3 mg/kg every 21 days for up to 4 doses) for whole-exosome sequencing (WES) and RNA-seq. Results: Twenty-one of 30 pts have been enrolled. Nine (43%) have received all 4 doses of IPI. IPI was discontinued prematurely in 9 pts (43%) due to drug-related toxicities and in 3 (14%) due to disease progression. All 3 of the latter had liver metastases. To date, tumors from 13 pts have been comprehensively analyzed by WES and RNA-seq. The median time from IPI #1 to the next systemic therapy for these pts was 24 weeks (IQR, 18.3 – 54.3). Responders (R) were defined as pts whose time to next systemic therapy was > 24 weeks. The median time to next systemic therapy for R (n = 7, 54%) is 55 weeks (IQR, 52.0 – 89.0; 2 pts with ongoing responses) versus 18 weeks (IQR, 10.5 – 23.0) for non-responders (NR; n = 6, 46%). In an analysis of all 13 pts, including those with liver metastases, tumor mutational load and frequency of expressed non-synonymous mutations were similar for R and NR pts. However, a subset analysis, excluding pts with liver metastases, revealed > 100 total mutations and/or > 10 expressed non-synonymous mutations in 7/7 R versus 1/4 NR. Conclusions: For advanced PCa pts without liver metastases, tumor mutational load may be associated with responses to IPI. Identification of immunodominant neoantigens may lead to the development of personalized vaccines to be combined with immune checkpoint therapies for the effective treatment of pts with PCa. Clinical trial information: NCT02113657.


  • A clinically applicable strategy to concurrently profile prostate cancer (PCa) in circulation and bone using high-definition single cell analysis (HD-SCA).

    by Amado J. Zurita, Anders Carlsson, Madelyn S. Luttgen, Kelly Bethel, Patricia Troncoso, Paul Gettys Corn, Anand Kolatkar, James B Hicks, Christopher Logothetis, Peter Kuhn

    5041 Background: The bone is the most significant organ site to characterize advanced PCa, but repeated bone biopsies are not feasible. Clinically relevant differences may exist between PCa clones in tissue and circulation, especially during therapy. To concurrently characterize tumor cells in blood (CTC) and bone in a clinically feasible manner, we adapted the HD-SCA platform to bone marrow aspirates (BMA). Methods: Peripheral blood and BMAs were obtained from individual patients with biochemically recurrent (BRPC; n = 52), metastatic hormone-naïve (mCSPC; n = 26) and metastatic castration-resistant (mCRPC; n = 63) PCa, before treatment or progressing on therapy. Eleven mCSPC and 59 mCRPC patients had bone metastasis. HD-SCA is a non-enrichment-based platform that allows for quantification of cell morphometry, protein expression and single cell genomic and proteomic analyses. Candidate tumor cells were defined as DAPI+/CK+/CD45-. Androgen receptor (AR) protein expression was also examined in single/clustered tumor cells. Clusters were defined as ≥ 2 tumor cells in direct contact, and their presence was correlated with survival outcomes. Whole genome copy number profiles (CNV) were obtained from single cancer cells. Results: Tumor cells were detected in 26% mCSPC and 39% mCRPC BMAs, while all BMAs from BRPC patients were negative. BMA status was concordant with corresponding BM biopsies (per clinical pathology assessment), but detection in BMAs was 45% more sensitive. Tumor cell clusters were more frequent, abundant and bigger in BMAs than in blood, expressed higher levels of AR per tumor cell, and were prognostic in mCRPC (both for progression-free and overall survival). Analysis of CNV profiles revealed distinct clonal patterns and distribution in BMA/blood from 3 patients with tumor cells present in both compartments. Conclusions: Our strategy allows for concurrent high-content profiling of CTCs and bone metastatic deposits in PCa patients. The simultaneous evaluation of the two liquid compartments resulted in novel insights into the prevalence and clinical significance of tumor cell clusters and clonal heterogeneity in advanced disease.

  • Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance.

    by Spyridon P Basourakos, John W. Davis, Brian Francis Chapin, John Francis Ward, Curtis Alvin Pettaway, Louis L. Pisters, Mary F. Achim, Xuemei Wang, Seungtaek Choi, Deborah A. Kuban, et al.

    5052 Background: Given the morbidities of and limited tumor tissue from prostate biopsies (BXs), circulating biomarkers distinguishing indolent from aggressive disease and predicting disease reclassification (DR) could transform early prostate cancer (PC) management. We have shown that caveolin-1 (Cav-1), a component of caveolae and cellular membrane, is secreted by PC cells, and implicated in the transition from high grade prostatic epithelial neoplasia to prostate cancer and associated with biochemical recurrence after prostatectomy. We evaluated Cav-1’s potential to predict DR during active surveillance (AS). Methods: In a single-institution prospective study, between 2006 and 2014, 825 patients (pts) with early PC were stratified to AS group (GR) I (favorable risk: Gleason score [GS]/single core of 3+3/ < 3 mm or 3+4/ < 2 mm and PSA < 4 ng/mL), II (pt choice), or III (comorbidities preventing local therapy). Pts had entry BX within 6 months of diagnostic BX and repeat BXs every 1–2 years. Tumor volume (TV) or grade increases prompted DR. PSA was measured every 6 months. Baseline plasma Cav-1 was measured in 542 pts using established ELISA in GR I and II pts. Univariate and multivariate logistic regression analyses assessed associations between patient clinicopathologic characteristics and DR. Results: Of 542 pts, 190 (35.1%) met GR I criteria; 352 (64.9%) met GR II criteria. Median age was 64 years; clinical stage cT1c was found in 88.6%; median PSA was 4.1 ng/mL; and GS was 3+3 in 87.3%. After a median of 3.1 years’ follow-up, 163 (30.1%) had met DR. Mean and median Cav-1 levels were 2.2 (SD, 8.5) ng/mL and 0.2 (range, 0, 85.5) ng/mL, respectively. By univariate analysis, log-transformed Cav-1 was a significant predictor for DR (p= .01; OR = 1.33). No association between Cav-1 and PSA or Cav-1 and testosterone was found. On multivariate analysis, adjusting for age, PSA, TV, and GR assignment, log-transformed Cav-1 remained significantly associated with DR (p= .04; OR = 1.27). Longitudinal Cav-1 plasma levels and tissue expression are under study. Conclusions: In a prospective AS cohort, plasma Cav-1 predicted DR independent of other parameters. If validated, results may refine patient selection for AS. Clinical trial information: NCT00490763.

  • Confirmatory analysis to determine associations between platinum-sensitivity, molecular signature of combined tumor suppressor defects and aggressive variant prostate carcinomas (AVPC).

    by Paul Gettys Corn, Elsa Li Ning Tapia, Lianchun Xiao, Elisabeth I. Heath, Haidee Chancoco, Anh Hoang, Eleni Efstathiou, Timothy C. Thompson, Patricia Troncoso, Christopher Logothetis, et al.

    5020 Background: Clinically defined AVPC is associated with platinum-sensitivity and a molecular profile of combined (≥2) alterations in PTEN, Tp53 and/or RB1 (Aparicio et al. Clin Cancer Res 2013;19 and Clin Cancer Res 2015;1). Based on these findings we conducted a validation study of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with CRPC stratified for the presence or absence of AVPC criteria (Corn et al. ASCO 2015; Funding: Sanofi). Methods: Clinical data were updated and available specimens were assembled for analysis. Immunohistochemistry was performed for AR, Ki67, RB1 and PTEN. DNA was extracted from remaining tumor cells and subject to next-generation sequencing to include Tp53. Results: At a median follow up of 21.6 months (mo), median progression free survival (mPFS) is 4.6 mo (95%CI 3.5-5.8) with CAB vs 7.4 mo (95% CI 5.6-8.3) with CAB/CARB (p = 0.004). In men meeting AVPC criteria, mPFS is 3.8 mo (95% CI 2.8-5.7) with CAB vs 5.6 mo (95% CI 4.4-8.0) with CAB/CARB (p = 0.012). After 86 deaths, median overall survival (mOS) is 17.4 mo (95% CI 12.6-25.9) with CAB vs 19.2 (95% CI 17.0-29.3) with CAB/CARB (p=0.489). 53% (42/79) of CAB patients and 23% (19/81) of CAB/CARB patients received additional salvage platinum-based therapy after progression. We identified 124 samples from 92 patients, of which 95 contained sufficient tumor for analysis. Of 54 analyzed to date, 38 belonged to men receiving CAB/CARB (30 AVPC) and 16 to men receiving CAB (10 AVPC). ≤10% of cells stained for AR, RB1 and PTEN in 6 (15%), 17 (42.5%) and 5 (12.5%) of 40 AVPC tumors and 0 (0%), 5 (35.7%) and 2 (14.3%) of non-AVPC tumors respectively. Tp53 sequencing is ongoing. Conclusions: Adding CARB to CAB is safe and significantly improves mPFS and response rates in men with mCRPC with a trend towards improved mOS. Men meeting AVPC clinical criteria benefit most from the CAB/CARB combination. We observed a high frequency of tumor suppressor defects in the characterized samples. Further analysis of the rate of their combination, association with AVPC criteria and benefit from CARB will be informative. Clinical trial information: NCT01505868.


  • A feasibility study to determine T cell responses to neoantigens following treatment with ipilimumab in men with metastatic castration-resistant prostate carcinoma (mCRPC).

    by Sumit Kumar Subudhi, Ana Aparicio, Patricia Troncoso, Jianhua Zhang, Curtis Gumbs, Chang-Jiun Wu, Luis M Vence, Christopher Logothetis, Andrew Futreal, James Patrick Allison, et al.

    E14506 Background: Ipilimumab (anti-CTLA-4) promotes durable antitumor responses in a subset of patients with mCRPC. We designed a clinical trial (NCT02113657) to test the hypothesis that the induction of an effective antitumor response by ipilimumab is mediated, at least in part, by lymphocyte responses to prostate cancer neoantigens. Methods: All patients (pts) enrolled into this clinical trial have tumor tissue biopsied or resected prior to receiving intravenous ipilimumab (3 mg/kg) every 21 days for a total of 4 doses. Mutations will be identified using whole-exome sequencing and RNA-seq. Peptides covering the expressed mutations will be synthesized and evaluated in in vitro studies for T cell responses prior to and after ipilimumab therapy. As target antigens for T cell assays, we will use synthetic 25mer peptides containing the given mutation derived from sequencing in its center, so that it is included at any position within a core epitope potentially recognized. Peptides containing putative mutated epitopes can be pooled and used to stimulate CD4 and CD8 T cells, following processing into naturally selected epitopes by CD4/CD8-depleted PBMCs, without the need to predefine alleles of HLA restriction. CD8 and CD4 T cell responses against mutant epitopes will be analyzed independently from peripheral blood mononuclear using IFN-gamma ELISPOT and intracellular multi-cytokine staining for functional recognition of antigen. Results: We have enrolled 14 of a total of 20 pts in this ongoing clinical trial, and 8 (57%) pts have received all 4 doses of ipilimumab. Ipilimumab was prematurely discontinued in 2 pts (14%) due to progression of disease and in 6 pts (43%) due to treatment-related toxicities including 2 pts (14%) who experienced grade 3 immune-related adverse events (irAEs). We have collected tumor tissues and PBMCs from 15 patients. Our studies are ongoing and data will be provided at the meeting. Conclusions: Identification of potential neoantigens in prostate tumors may facilitate future combination therapy studies with personalized vaccines and immune checkpoint agents for the effective treatment of patients with prostate cancer.

  • A comprehensive molecular characterization of aggressive variant prostate cancer (PC).

    by Ana Aparicio, Li Shen, Elsa Li Ning Tapia, Jing-Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Bradley McIntosh Broom, et al.

    149 Background: Unusually aggressive PC behavior is linked to small cell carcinoma (SCC) morphology. We observed SCC clinical features in association with morphologically heterogeneous PC and, in a prospective clinical trial (NCT00514540), also with chemotherapy responsiveness. Our previous studies in patient derived xenografts (PDX) revealed a distinct molecular profile for SCC. Here we sought to support the hypothesis that clinically defined aggressive variant PCs also share relevant biology with SCC. Methods: 59 PC samples, and 8 PDX, from 42 men registered to NCT00514540 were stained for RB, p53, AR, NKX3-1, ASCL1, AURKA, UBE2C and Ki67. Labeling indices (LI) were calculated as the ratio of positive epithelial cells to total of epithelial cells, at 200x. We determined copy number alterations (CNA) by Onco Scan® in 36 of 59 samples and 8 PDX lines. We used Western Blot and qRT-PCR to expand pathway analyses and their associations in PDX models. Results: Donor patients were similar to non-donor patients except for higher ECOG PS and LDH values. Strong positive correlations between nuclear AR (AR-N) and NKX3.1, AR-N and RB, AR-N and nuclear AURKA (AURKA-N), NKX3.1 and RB, p53 and nuclear UBE2C (UBE2C-N), Ki67 and UBE2C-N, Ki67 and cytoplasmic UBE2C (UBE2C-C) as well as a strong negative correlation between NKX3.1 and Ki 67 were observed. Frequent copy number losses were found for PTEN (largely gene-specific) and RB1 (often associated with regional-CNA). Gene-specific AURKA amplifications were not observed. Only RB1 CNA showed a positive correlation with its LI. Samples were segregated by quantity of CNA. PDX models shared these features and showed that only AR-negative tumors expressed pro-neural transcription factors, albeit heterogeneously. Conclusions: Our results support the hypothesis that clinically defined aggressive variant PC (including SCC and non-SCC morphologies) are characterized by frequent Rb, p53 and PTEN alterations, aberrant expression of mitotic, neural development and AR-signaling pathways, and high rates of CNA. Ongoing studies will confirm whether these molecular features distinguish this variant from the more common bone-homing, bone-forming, AR-driven adenocarcinomas of the prostate.